<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>KRAS mutations are frequent in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and are associated with clinical resistance to treatment with the epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies </plain></SENT>
<SENT sid="1" pm="."><plain>Delta-like 4 ligand (DLL4) is an important component of the Notch signaling pathway and mediates stem cell self-renewal and vascular development </plain></SENT>
<SENT sid="2" pm="."><plain>DLL4 inhibition in <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> cells reduces <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and stem cell frequency </plain></SENT>
<SENT sid="3" pm="."><plain>Considering the need for new drugs to treat <z:hpo ids='HP_0003003'>colon cancers</z:hpo> with oncogenic KRAS mutations, we examined in this study the efficacy of anti-DLL4 antibodies in KRAS mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in a panel of early passage <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> derived from patients </plain></SENT>
<SENT sid="4" pm="."><plain>Consistent with clinical findings, mutant KRAS colorectal xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were insensitive to the EGFR therapeutic antibody cetuximab, whereas KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> responded to cetuximab </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, anti-DLL4 was efficacious against both <z:mp ids='MP_0002169'>wild-type</z:mp> and mutant KRAS <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumors</z:e> as a single agent and in combination with irinotecan </plain></SENT>
<SENT sid="6" pm="."><plain>Further analysis of mutant KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> indicated that the anti-DLL4/irinotecan combination produced a significant decrease in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> stem cell frequency while promoting <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Our findings provide a rationale for targeting DLL4-Notch signaling for improved treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with activating KRAS mutations </plain></SENT>
</text></document>